Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BTIG analyst Mark Massaro maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $210 to $230.
Natera (NASDAQ:NTRA) raises FY2025 sales outlook from $2.020 billion-$2.100 billion to $2.180 billion-$2.260 billion vs $2.091 ...
Natera (NASDAQ:NTRA) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.40) by 6...
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) and precision medicine, today announced it will expand its...
BTIG analyst Mark Massaro maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $200 to $210.
Data to be featured in Presidential Symposium at ESMOSignatera™ changes the paradigm by expanding the adjuvant decision window,...
